Biohaven achieves positive results in pivotal study September 23 2024 Biohaven Ltd have announced positive topline results from pivotal Study BHV4157-206-RWE (NCT06529146) demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after 3 years of treatment. The study achieved the primary endpoint and showed statistically significant improvements on the f-SARA…
Category: Movement Disorders
Deutetrabenazine for Tardive Dyskinesia
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients 21st September 2024: Teva Pharmaceutical Industries Ltd has announced that a new analysis from the European cohort of the RIM-TD open-label extension (OLE) study revealed that deutetrabenazine treatment of patients with Tardive Dyskinesia (TD) was associated with long term improvement of TD symptoms….
